Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV)

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 556-561

  Wegzyn, Colleen M ^a   Wyles, David L ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; COBICISTAT; CYCLOPHILIN INHIBITOR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL PLUS ELVITEGRAVIR PLUS COBICISTAT; HISTAMINE H2 RECEPTOR ANTAGONIST; INCIVIK; INTEGRASE INHIBITOR; LOMIBUVIR; LOPINAVIR PLUS RITONAVIR; MK 5172; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; QUAD; RIFAMPICIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; TM 278; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR;

ANEMIA; ANTIVIRAL THERAPY; DEPRESSION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; GENOTYPE; HEADACHE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; TABLET; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS;

EID: 84867332475     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.005     Document Type: Review

References (37)

1. K.N. Ly, J. Xing, R.M. Klevens, R.B. Jiles, J.W. Ward, and S.D. Holmberg The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 2012 271 278
2. M.J. Alter Epidemiology of viral hepatitis and HIV co-infection J. Hepatol 44 1 Suppl. 2006 S6 S9
3. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Müh, M. Welker, D. Wincheringer, Y. Zhou, H.-M. Chu, and C. Lin Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
4. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, U. Karey, E. Hughes, R. Ralston, X. Tong, and E. Herrmann Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
5. M. Sulkowski, D. Gardiner, E. Lawitz, F. Hinestrosa, D. Nelson, P. Thuluvath, M. Rodriguez-Torres, A. Lok, H. Schwartz, and K.R. Reddy 1422 Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, OR 3 J Hepatol 56 Suppl. 2(0) 2012 S560
6. F. Poordad, E. Lawitz, K.V. Kowdley, G.T. Everson, B. Freilich, D. Cohen, S. Siggelkow, M. Heckaman, R. Menon, and T.P. Matias 1399 12-Week interferon-free regimen of ABT-450/R +ABT-333 +ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders J Hepatol 56 Suppl. 2(0) 2012 S549 S550
7. E.J. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, R.G. Hindes, and M.M. Berrey 1113 Electron: once daily PSI-7977 plus RBV in HCV GT1/2/3 J Hepatol 56 Suppl. 2(0) 2012 S438 S439
8. Edurant Prescribing Information. Raritan, NJ: Tibotec, Inc.; 2011.
9. H. Crauwels, J. Vingerhoets, R. Ryan, J. Witek, and D. Anderson Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects [Internet] Antivir Ther 2011 Available from: http://www.ncbi.nlm.nih.gov/pub
10. C. Cohen, J. Molina, P. Cahn, B. Clotet, J. Fourie, B. Grinsztejn, H. Wu, M. Johnson, M. Saag, and K. Supparatpinyo Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials [Internet] J Acquir Immune Defic Syndr 2012 [cited 2012 Feb 29] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22343174
11. E. DeJesus, D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, and A. Cheng Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment naive and treatment experienced patients J Acquir Immune Defic Syndr 43 2006 1 5
12. S. Ramanathan, A.A. Mathias, P. German, and B.P. Kearney Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir Clin Pharmacokinet 50 2011 229 244
13. A. Mathias, S. Ramanathan, J. Hinkle, S. West, J. Enejosa, and B. Kearney Effect of atazanavir/r on the steady state pharmacokinetcs of elvitegravir [abstract n A-1417] 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; September 17-20 2007
14. A. Mathias, S. West, J. Enejosa, and B. Kearney A pharmacokinetic interaction between lopinavir/r and elvitegravir [abstract n A-1418] 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; September 17-20 2007
15. S. Ramanathan, J. Hinkle, J. Enejosa, and B. Kearney Pharmacokinetic evaluation of drug interactions with ritonavir boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents [abstract no. 69] 8th International Workshop on Clinical Pharmacology of HIV Therapy Budapest, Hungary; April 16-18 2007
16. A. Mathias, P. German, B. Murray, L. Wei, A. Jain, S. West, D. Warren, J. Hui, and B. Kearney Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity Clin Pharmacol Ther 87 2010 322 329
17. P. German, D. Warren, S. West, J. Hui, and B. Kearney Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV J Acquir Immune Defic Syndr 55 2010 323 329
18. E.I. Lepist, B.P. Murray, L. Tong, A. Roy, R. Bannister, and A.S. Ray Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [Abstract A1-1724] 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, IL; September 17-20 2011
19. P. German, C. Liu, D. Warren, M. Hepner, J. Andrews, B. Kearney, and A. Mathias Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function [Abstract H2-804] 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; September 17-20 2011
20. P. Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl, J. Gallant, H. Liu, E. Quirk, and B. Kearney Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment naïve HIV-1 infected subjects [Abstract 101] 19th Conference of Retroviruses and Opportunistic Infections Seattle, WA; March 4-5 2012
21. E. DeJesus, J. Rockstroh, K. Henry, J.-M. Molina, J. Gathe, S. Ramanathan, X. Wei, J. Szwarcberg, A. Jandourek, and A. Cheng Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/ emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment naïve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics [Abstract 627] 19th Conference of Retroviruses and Opportunistic Infections Seattle, WA; March 4-5 2012
22. E. DeJesus, C. Cohen, R. Elion, R. Ortiz, L. Maroldo, S. Franson, and R. Pesano First report of raltegravir (RAL, MK-0518) use after virological rebound on elvitegravir (EVT, GS 9137) [Abstract TUPEB032] 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention Sydney; July 2007
23. Victrelis (boceprevir) Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2011.
24. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, and N. Boparai Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
25. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, and N. Boparai Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
26. Incivek (telaprevir) Package Insert. Cambridge, MA: Vertex Pharmaceuticals Inc; 2011.
27. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, and R. Flisiak Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
28. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, G.T. Everson, M.W. Fried, M. Adler, H.W. Reesink, and M. Martin Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
29. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, and A. Horban Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
30. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir [Internet] Hepatology (Baltimore, MD) 2012 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/22331658
31. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, I. Jacobson, and P. Marcellin TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the pillar phase IIB study Hepatology 54 4 Suppl. 2011 1429A
32. S. Pol, Rust, C. Martorell, G. Everson, H. Tatum, C. Hezode, J. Lim, J. Bronowicki, G.A. Abrams, and N. Brau High rates of SVR24 for BMS-790052, an NS5A replication complex inhibitor, in combination with PegIFN-alfa-2a and ribavirin: phase 2a trial in treatment-naive HCV genotype 1 subjects [Abstract H1-376] 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, IL; September 17-20 2011
33. K.V. Kowdlev, E. Läwitz, I. Crespo, T. Hassanein, M. Davis, M. DeMicco, D.R. Nelson, D. Bernstein, N.H. Afdhal, and I. Jacobson 1 Atomic: 97% RVR for PSI-7977 + PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy? J Hepatol 56 Suppl. 2(0) 2012 S1
34. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, and M. Wind-Rotolo Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
35. E. Hulskotte, H.P. Feng, F. Xuan, M. van Zutven, E. O'Mara, S. Youngberg, J. Wagner, and J. Butterton Pharmacokinetic interaction between the HCV protease inhibitor Boceprevir and ritonavir-boosted HIV-1 protease inhibitors Atazanavir, Lopinavir, and Darunavir [Abstract 771LB] 19th Conference of Retroviruses and Opportunistic Infections Seattle, WA; March 4-5 2012
36. C. de Kanter, M. Blonk, A. Colbers, Q. Fillekes, B. Schouwenberg, and D. Burger Influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [Abstract 772LB] 19th Conference of Retroviruses and Opportunistic Infections Seattle, WA; March 4-5 2012
37. R. Van Heeswiijk, V. Garg, G. Boogaerts, A. Vandenbosch, D. Luo, J. Witek, and B. Dannenmann The pharmacokinetics between telaprevir and raltegravir in healthy volunteers [Abstract A1-1738a] 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, IL; September 17-20 2011